We receive funding from a variety of sources that recognize the value of our high-impact research.
Julian Ambrus, Jr., MD
- Novel Role for the P2Y2 Receptor in the Autoimmune Disease Sjögren’s Syndrome. Julian Ambrus, Jr. (Co-Investigator). NIDCR. 1/1/2017-12/1/2022.
Supriya Mahajan, PhD, MPH
- A novel phase and spectroscopic imaging technique to evaluate mitochondrial dynamics. Supriya Mahajan (Principal Investigator). National Institute of Drug Abuse (NIDA). $1,200,000. 2/1/2019-1/1/2022.
- Inhibition of Radiation-Induced Coronary Microvascular Disease. Supriya Mahajan (Co-Investigator). NIH. $1,750,000. 9/1/2020-8/1/2025.
- Biomarkers for Type III Hereditary Angioedema. Supriya Mahajan (Co-Investigator). Takeda originally Shire. $275,000. 1/1/2018-12/1/2023.
- Oral Microbiome in HIV+ patients with Thrush. Supriya Mahajan (Principal Investigator). Buffalo Blue Sky Award UB VPR Office. $35,000. 1/1/2020-3/1/2022.
Jessica Reynolds, PhD
- Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB. Jessica Reynolds (Principal Investigator). NIAID. $2,197,275. 8/1/2018-7/1/2023.
- A pilot placebo-controlled randomized double-blind trial of Melatonin. Jessica Reynolds (Co-Investigator). 1/1/2021-3/1/2022.
- Discovery of Drugs Targeting Melatonin Receptors to Abrogate Methamphetamine Use. Jessica Reynolds (Co-Principal Investigator). 10/1/2020-3/1/2022.
- KL2 Mentored Career Development Program (KL2 Program)- Buffalo Clinical and Translational Research Center. Jessica Reynolds (Co-Investigator). 9/1/2019-3/1/2023.
Stanley Schwartz, M.D., Ph.D.
- A Multimodal Hierarchical Theranostic Nanoparticle for Castration Resistant Prostate Cance. Stanley Schwartz (Principal Investigator). Department of Veterans Affairs. 1/1/2022-12/1/2025.